Drug intelligence / Profile preview

AC4-CDDP4

Development stage: Preclinical
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

AC4-CDDP4 is a platinum-based chemotherapeutic agent under investigation for cancer treatment. It functions by forming platinum-DNA adducts, which prevent DNA replication and transcription, ultimately leading to apoptosis of cancer cells. This mechanism is characteristic of platinum compounds used in oncology, such as cisplatin. The compound is being studied as part of combination chemotherapy regimens for various cancers[1][2].

Targets

DNA

Beyond the preview

Go deeper on AC4-CDDP4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC4-CDDP4.

Explore the full profile